carfilzomib   Click here for help

GtoPdb Ligand ID: 7420

Synonyms: Kyprolis® | PR-171
Approved drug
carfilzomib is an approved drug (FDA (2012), EMA (2015))
Compound class: Synthetic organic
Comment: Carfilzomib is a tetrapeptide analogue of epoxomicin, an Actinomycete derived selective proteasome inhibitor [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 12
Hydrogen bond donors 4
Rotatable bonds 24
Topological polar surface area 158.47
Molecular weight 719.43
XLogP 3.71
No. Lipinski's rules broken 2
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC(CC(C(=O)NC(C(=O)NC(C(=O)C1(C)CO1)CC(C)C)Cc1ccccc1)NC(=O)C(NC(=O)CN1CCOCC1)CCc1ccccc1)C
Isomeric SMILES CC(C[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)[C@@]1(C)CO1)CC(C)C)Cc1ccccc1)NC(=O)[C@@H](NC(=O)CN1CCOCC1)CCc1ccccc1)C
InChI InChI=1S/C40H57N5O7/c1-27(2)22-32(36(47)40(5)26-52-40)42-39(50)34(24-30-14-10-7-11-15-30)44-38(49)33(23-28(3)4)43-37(48)31(17-16-29-12-8-6-9-13-29)41-35(46)25-45-18-20-51-21-19-45/h6-15,27-28,31-34H,16-26H2,1-5H3,(H,41,46)(H,42,50)(H,43,48)(H,44,49)/t31-,32-,33-,34-,40+/m0/s1
InChI Key BLMPQMFVWMYDKT-NZTKNTHTSA-N
References
1. Hanada M, Sugawara K, Kaneta K, Toda S, Nishiyama Y, Tomita K, Yamamoto H, Konishi M, Oki T. (1992)
Epoxomicin, a new antitumor agent of microbial origin.
J Antibiot, 45 (11): 1746-52. [PMID:1468981]
2. Kuhn DJ, Chen Q, Voorhees PM, Strader JS, Shenk KD, Sun CM, Demo SD, Bennett MK, van Leeuwen FW, Chanan-Khan AA et al.. (2007)
Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma.
Blood, 110 (9): 3281-90. [PMID:17591945]
3. Zhou HJ, Aujay MA, Bennett MK, Dajee M, Demo SD, Fang Y, Ho MN, Jiang J, Kirk CJ, Laidig GJ et al.. (2009)
Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047).
J Med Chem, 52 (9): 3028-38. [PMID:19348473]